Document text
Principal Investigator: Mark Morris Davis
Organization: STANFORD UNIVERSITY
Fiscal Year: 2024
Award: $132,036
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
The administrative core of the Stanford CCHI has been highly successful in the past almost twenty years in its
leadership and coordination of center activities, management of finances and resources, and facilitation of
intra-center collaboration and scientific support. The continued success of the Stanford CCHI will rely upon the
effectiveness of its administrative core. Dr. Mark Davis will remain in his role as overall Pl of the Stanford CCHI
and as the core lead for this core. He will also chair the executive committee consisting of the other project
and core leaders (Ors. Wang, Barnes, Khatri, Maecker and Chinthrajah) who will be responsible for the overall
organization, management, decision-making, and periodic evaluations within the Stanford CCHI. In addition,
they will oversee resource allocation, protection of intellectual property in conjunction with Stanford's Office of
Technology Licensing, and the involvement of other institutional resources. Dr. Jasprina Noordermeer and Ms.
Michele King will be assisting Dr. Davis to monitor overall progress, provide support to the administrative
leadership team, and coordinate center activities and collaborations. They will be joined by Dr. Molly Miranda,
who will oversee data management and sharing and upload of data to lmmPort according to the procedures
outlined in the Data Management and sharing Plan.
Terms: <2019-nCoV vaccine><Business-Friendly Atmosphere><COVID-19 vaccine><Collaborations><Communication><Data><Decision Making><Deposit><Deposition><Effectiveness><Evaluation><Grippe><In Vitro><Influenza><Institution><Intellectual Property><Lead><Leadership><Licensing><Mollies><Monitor><Pb element><Periodicals><Procedures><Research Resources><Resolution><Resource Allocation><Resources><Role><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Technology><business-friendly environment><collaborative atmosphere><collaborative environment><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><data management><data sharing><heavy metal Pb><heavy metal lead><in vivo><interactive atmosphere><interactive environment><interdisciplinary atmosphere><interdisciplinary environment><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><peer-group atmosphere><peer-group environment><periodic><periodical><resolutions><social role><success><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine response><vaccine responsiveness><vaccine-induced response><vaccines preventing COVID><vaccines to prevent COVID>